BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 23090076)

  • 1. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
    Lim SN; Kuhn S; Hyde E; Ronchese F
    J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocyte-derived DC primed with TLR agonists secrete IL-12p70 in a CD40-dependent manner under hyperthermic conditions.
    Peng JC; Hyde C; Pai S; O'Sullivan BJ; Nielsen LK; Thomas R
    J Immunother; 2006; 29(6):606-15. PubMed ID: 17063123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy.
    Harada S; Kimura T; Fujiki H; Nakagawa H; Ueda Y; Itoh T; Yamagishi H; Sonoda Y
    Int J Oncol; 2007 Jun; 30(6):1461-8. PubMed ID: 17487367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
    Feili-Hariri M; Falkner DH; Morel PA
    J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrinsic ability of GM+IL-4 but not Flt3L-induced rat dendritic cells to promote allogeneic T cell hyporesponsiveness.
    Taieb A; Breitinger JJ; Unadkat JV; Shufesky WJ; Morelli AE; Thomson AW; Lee WP; Feili-Hariri M
    Clin Immunol; 2007 May; 123(2):176-89. PubMed ID: 17276735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
    Mach N; Gillessen S; Wilson SB; Sheehan C; Mihm M; Dranoff G
    Cancer Res; 2000 Jun; 60(12):3239-46. PubMed ID: 10866317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.
    Weigel BJ; Nath N; Taylor PA; Panoskaltsis-Mortari A; Chen W; Krieg AM; Brasel K; Blazar BR
    Blood; 2002 Dec; 100(12):4169-76. PubMed ID: 12393694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes.
    Conti L; Cardone M; Varano B; Puddu P; Belardelli F; Gessani S
    Eur J Immunol; 2008 Mar; 38(3):750-62. PubMed ID: 18236400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells.
    Renneson J; Salio M; Mazouz N; Goldman M; Marchant A; Cerundolo V
    Clin Exp Immunol; 2005 Mar; 139(3):468-75. PubMed ID: 15730392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggering.
    Bracci L; Schumacher R; Provenzano M; Adamina M; Rosenthal R; Groeper C; Zajac P; Iezzi G; Proietti E; Belardelli F; Spagnoli GC
    J Immunother; 2008 Jun; 31(5):466-74. PubMed ID: 18463538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17 is a potent synergistic factor with GM-CSF in mice in stimulating myelopoiesis, dendritic cell expansion, proliferation, and functional enhancement.
    Liu B; Tan W; Barsoum A; Gu X; Chen K; Huang W; Ramsay A; Kolls JK; Schwarzenberger P
    Exp Hematol; 2010 Oct; 38(10):877-884.e1. PubMed ID: 20600582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy.
    Berhanu A; Huang J; Alber SM; Watkins SC; Storkus WJ
    Cancer Res; 2006 May; 66(9):4895-903. PubMed ID: 16651446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
    Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
    Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stimulatory effect of TLRs ligands on maturation of chicken bone marrow-derived dendritic cells.
    Liang J; Fu J; Kang H; Lin J; Yu Q; Yang Q
    Vet Immunol Immunopathol; 2013 Sep; 155(3):205-10. PubMed ID: 23876303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells induced in the presence of GM-CSF and IL-5.
    Yi H; Zhang L; Zhen Y; He X; Zhao Y
    Cytokine; 2007 Jan; 37(1):35-43. PubMed ID: 17382554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.
    Brossart P; Zobywalski A; Grünebach F; Behnke L; Stuhler G; Reichardt VL; Kanz L; Brugger W
    Cancer Res; 2000 Aug; 60(16):4485-92. PubMed ID: 10969796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradermal delivery of TLR agonists in a human explant skin model: preferential activation of migratory dendritic cells by polyribosinic-polyribocytidylic acid and peptidoglycans.
    Oosterhoff D; Heusinkveld M; Lougheed SM; Kosten I; Lindstedt M; Bruijns SC; van Es T; van Kooyk Y; van der Burg SH; de Gruijl TD
    J Immunol; 2013 Apr; 190(7):3338-45. PubMed ID: 23467931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.